Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314083 | 0.88 | CRBN (0.43) | DDB1CRBNALDH1A1 | |
| SCHEMBL26141981 | 0.82 | GPR139 (0.35) | GPR139DDB1CRBNALDH1A1PARP1 | |
| SCHEMBL22511869 | 0.73 | CRBN (0.35) | DDB1CRBNALDH1A1 | |
| SCHEMBL20436926 | 0.73 | DDB1 (0.35) | DDB1CRBN | |
| SCHEMBL26138573 | 0.71 | CRBN (0.40) | DDB1CRBNALDH1A1PARP1 | |
| SCHEMBL26147530 | 0.70 | CRBN (0.43) | DDB1CRBNALDH1A1 | |
| SCHEMBL25847908 | 0.68 | ALDH1A1 (0.36) | DDB1CRBNSMN1; SMN2ALDH1A1 | |
| SCHEMBL20046865 | 0.68 | CRBN (0.47) | DDB1CRBNALDH1A1 | |
| SCHEMBL26141975 | 0.68 | CRBN (0.54) | DDB1CRBNALDH1A1 | |
| SCHEMBL21477243 | 0.68 | CRBN (0.51) | DDB1CRBNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | GPR139 4808/4885DDB1 706/4885CRBN 74/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | GPR139 4225/4885DDB1 987/4885CRBN 179/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | GPR139 4808/4885DDB1 706/4885CRBN 74/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | GPR139 4310/4885DDB1 576/4885CRBN 163/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | GPR139 4808/4885DDB1 706/4885CRBN 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.